FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency (SAMHSA)
Trending Reports
-
DEA Toxicology Testing Program – 2022 Q1 Report May 20, 2022
-
Recommended Scope for NPS Testing in the United States: Q1 2022 May 12, 2022
-
NPS Alert: Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replace Eutylone in Drug Supply Typically Sold as “Ecstacy” or “Molly” April 22, 2022
-
Trend Report: NPS Opioids in the US – Q1 2022 April 12, 2022
-
Trend Report: NPS Stimulants & Hallucinogens in the US – Q1 2022 April 12, 2022